Developer docs
API playgroundTry for free, no card

Search company profiles

ESN Cleer

Full company profile

uuid0004eht

Namestring
ESN Cleer
Legal namestring
Endothelium Scanning Nanotechnology Ltd.
Websiteurl
cleer.com.au
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
repurposed drug development, orphan cardiomyopathy drugs, cardiovascular therapeutics, precision medicine biopharmaceuticals, rare disease drug development
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Orphan Cardiomyopathy Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialisation
TypeLicensing Royalties
Description

Pre-revenue biotech company developing repurposed drugs for orphan indications. Anticipated licensing and M&A opportunities to support growth. Revenue expected through drug commercialisation upon regulatory approval.

cleer.com.au
2Orphan Drug Commercialisation
TypeOne Time License
Description

Targeting orphan drug market projected to reach US$300b reaching 20% of all drug sales by 2028. US Government's Orphan Drug Act provides substantial incentives including Medicare and Medicaid coverage.

cleer.com.au
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ESNtx005
Description

Repurposed drug developed by ESN Cleer targeted to specific rare disease subgroups within the Cardiomyopathy market segment, featuring novel composition of matter and precision medicine approach.

cleer.com.au
Core offering1 text field

ESN Cleer is a pre-revenue biopharmaceutical company developing repurposed drugs for orphan indications in cardiomyopathies. Its lead product, ESNtx005, is a proprietary repurposed drug with novel composition of matter targeting specific rare disease subgroups within the cardiomyopathy market segment, using a precision medicine approach to accelerate clinical development. The company intends to commercialise through licensing deals and M&A with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Significant reduction in development cost, time and risks compared to traditional drug development
Product overview1 text field

ESN Cleer is a precision therapeutics company developing repurposed drugs for orphan indications in cardiomyopathies. Its primary product is ESNtx005, a repurposed drug targeting rare disease subgroups within the cardiomyopathy market segment. The company leverages a de-risked development approach with regulatory advantages through orphan drug pathways.

Product and service1 record
1ESNtx005
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent renowned global healthcare and life sciences sector services provider. ESN's regulatory and market access is at 70% Optimising phase, well-advanced towards commercialisation.

2Elion
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent Intellectual Property legal powerhouse for biotech and Medtech industry. ESN's IP protection (market access/exclusivity/value) is at an astounding 80% rating.

cleer.com.au
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage rare-disease biotech with a leading cardiomyopathy program (acoramidis for ATTR-CM). Highly comparable to ESN Cleer as a rare/precision cardiovascular company pursuing orphan cardiac indications.

TypeDirect peer
Description

Cardiovascular-focused biotech developing cardiac myosin modulators for heart failure and cardiomyopathies. Comparable target indication (heart failure with preserved/mid-range ejection fraction and HCM) and orphan cardiovascular commercial thesis.

TypeEmerging player
Description

Genetic medicines company developing therapies for cardiomyopathies and rare cardiac diseases. Comparable rare cardiomyopathy focus with a precision-medicine approach to genetic heart disease.

4Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage company developing elamipretide for rare mitochondrial cardiomyopathies including Barth syndrome. Directly comparable as an orphan/rare cardiomyopathy drug developer.

TypeEmerging player
Description

Clinical-stage gene therapy company with cardiomyopathy programs (e.g., Friedreich's ataxia cardiomyopathy). Comparable rare cardiac disease focus and small-cap clinical biotech profile.

TypeEmerging player
Description

European clinical-stage biotech developing RNA-based therapeutics for heart failure and cardiac remodeling. Comparable in size, stage, and orphan/precision cardiovascular therapeutic positioning.

TypeEmerging player
Description

Clinical-stage biotech developing novel cardiometabolic therapies for heart failure with preserved ejection fraction. Comparable orphan/precision cardiology positioning.

TypeEmerging player
Description

Late-stage gene therapy company with cardiac programs targeting rare inherited cardiomyopathies (e.g., Danon disease). Comparable rare cardiac disease focus and small-cap clinical biotech status.

TypeBroad incumbent
Description

Global pharmaceutical company with a dominant heart failure franchise (Entresto/sacubitril-valsartan). Comparable as the incumbent standard-of-care in heart failure that ESNtx005's orphan subgroups would be measured against.

TypeBroad incumbent
Description

Established orphan-disease RNA therapeutics company with a commercial cardiomyopathy asset (Onpattro/Amvuttra-related, and patisiran/Amvuttra in ATTR-CM). Comparable as a successful orphan-cardiology commercial benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ESN Cleer

Orphan Cardiomyopathy Biopharmaceuticalscleer.com.au

ESN Cleer firmographics

Firmographics
Name
ESN Cleer
Legal name
Endothelium Scanning Nanotechnology Ltd.
Website
https://cleer.com.au
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

ESN Cleer industry classification

Industry
Product category
Orphan Cardiomyopathy Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Repurposed drug development
  • Orphan cardiomyopathy drugs
  • Cardiovascular therapeutics
  • Precision medicine biopharmaceuticals
  • Rare disease drug development

Where ESN Cleer is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

ESN Cleer business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialisation: Pre-revenue biotech company developing repurposed drugs for orphan indications. Anticipated licensing and M&A opportunities to support growth. Revenue expected through drug commercialisation upon regulatory approval.
  2. Orphan Drug Commercialisation: Targeting orphan drug market projected to reach US$300b reaching 20% of all drug sales by 2028. US Government's Orphan Drug Act provides substantial incentives including Medicare and Medicaid coverage.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

ESN Cleer product offering

Product offering

Core offering

ESN Cleer is a pre-revenue biopharmaceutical company developing repurposed drugs for orphan indications in cardiomyopathies. Its lead product, ESNtx005, is a proprietary repurposed drug with novel composition of matter targeting specific rare disease subgroups within the cardiomyopathy market segment, using a precision medicine approach to accelerate clinical development. The company intends to commercialise through licensing deals and M&A with pharmaceutical partners.

Product overview

ESN Cleer is a precision therapeutics company developing repurposed drugs for orphan indications in cardiomyopathies. Its primary product is ESNtx005, a repurposed drug targeting rare disease subgroups within the cardiomyopathy market segment. The company leverages a de-risked development approach with regulatory advantages through orphan drug pathways.

Differentiator

Problem solved

Functional benefit

Brands

  • ESNtx005: Repurposed drug developed by ESN Cleer targeted to specific rare disease subgroups within the Cardiomyopathy market segment, featuring novel composition of matter and precision medicine approach.

Products and services

  • ESNtx005

Quantifiable outcome

  • Significant reduction in development cost, time and risks compared to traditional drug development

Companies that use ESN Cleer

Customer profile

Segments1 record

Ideal customer profiles2 records

ESN Cleer technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ESN Cleer partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Alira HealthcoreStrategic or Co-development PartnerIndependent renowned global healthcare and life sciences sector services provider. ESN's regulatory and market access is at 70% Optimising phase, well-advanced towards commercialisation.
  • ElioncoreStrategic or Co-development PartnerIndependent Intellectual Property legal powerhouse for biotech and Medtech industry. ESN's IP protection (market access/exclusivity/value) is at an astounding 80% rating.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

ESN Cleer competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: Clinical-stage rare-disease biotech with a leading cardiomyopathy program (acoramidis for ATTR-CM). Highly comparable to ESN Cleer as a rare/precision cardiovascular company pursuing orphan cardiac indications.
  • Cytokinetics: Cardiovascular-focused biotech developing cardiac myosin modulators for heart failure and cardiomyopathies. Comparable target indication (heart failure with preserved/mid-range ejection fraction and HCM) and orphan cardiovascular commercial thesis.
  • Stealth BioTherapeutics: Clinical-stage company developing elamipretide for rare mitochondrial cardiomyopathies including Barth syndrome. Directly comparable as an orphan/rare cardiomyopathy drug developer.

Emerging players

  • Tenaya Therapeutics: Genetic medicines company developing therapies for cardiomyopathies and rare cardiac diseases. Comparable rare cardiomyopathy focus with a precision-medicine approach to genetic heart disease.
  • Lexeo Therapeutics: Clinical-stage gene therapy company with cardiomyopathy programs (e.g., Friedreich's ataxia cardiomyopathy). Comparable rare cardiac disease focus and small-cap clinical biotech profile.
  • Cardior Pharmaceuticals: European clinical-stage biotech developing RNA-based therapeutics for heart failure and cardiac remodeling. Comparable in size, stage, and orphan/precision cardiovascular therapeutic positioning.
  • Imbria Pharmaceuticals: Clinical-stage biotech developing novel cardiometabolic therapies for heart failure with preserved ejection fraction. Comparable orphan/precision cardiology positioning.
  • Rocket Pharmaceuticals: Late-stage gene therapy company with cardiac programs targeting rare inherited cardiomyopathies (e.g., Danon disease). Comparable rare cardiac disease focus and small-cap clinical biotech status.

Broad incumbents

  • Novartis (Entresto franchise): Global pharmaceutical company with a dominant heart failure franchise (Entresto/sacubitril-valsartan). Comparable as the incumbent standard-of-care in heart failure that ESNtx005's orphan subgroups would be measured against.
  • Alnylam Pharmaceuticals: Established orphan-disease RNA therapeutics company with a commercial cardiomyopathy asset (Onpattro/Amvuttra-related, and patisiran/Amvuttra in ATTR-CM). Comparable as a successful orphan-cardiology commercial benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ESN Cleer social profiles

Digital presence

ESN Cleer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ESN Cleer leadership team

Management profile

Number of profiles

Profiles11 records

ESN Cleer funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ESN Cleer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ESN Cleer

What does ESN Cleer do?

ESN Cleer is a pre-revenue biopharmaceutical company developing repurposed drugs for orphan indications in cardiomyopathies. Its lead product, ESNtx005, is a proprietary repurposed drug with novel composition of matter targeting specific rare disease subgroups within the cardiomyopathy market segment, using a precision medicine approach to accelerate clinical development. The company intends to commercialise through licensing deals and M&A with pharmaceutical partners.

Is ESN Cleer a public or private company?

ESN Cleer is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ESN Cleer founded?

ESN Cleer was founded in 2018. It employs 1 to 10 people.

Where is ESN Cleer based?

ESN Cleer is headquartered in Melbourne, Australia, in the Oceania region.

How does ESN Cleer make money?

Two revenue lines are on record. Drug Development and Commercialisation is the primary driver. The others are orphan Drug Commercialisation.

Who are ESN Cleer's main competitors?

Direct peers on record are BridgeBio Pharma, Cytokinetics and Stealth BioTherapeutics. Emerging players are Tenaya Therapeutics, Lexeo Therapeutics, Cardior Pharmaceuticals, Imbria Pharmaceuticals and Rocket Pharmaceuticals. Broad incumbents are Novartis (Entresto franchise) and Alnylam Pharmaceuticals.

Does ESN Cleer have an API?

No public API is recorded for ESN Cleer.

What industry is ESN Cleer in?

ESN Cleer's product category is Orphan Cardiomyopathy Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals